NCT04034485 — "Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH" trial site landscape

Public-registry site landscape for NCT04034485, “Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH”, a Homozygous Familial Hypercholesterolemia study sponsored by LIB Therapeutics LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT04034485 (registry record)
Study title	Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH
Official title	Randomized, Open-Label, Cross-Over, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy
Sponsor	LIB Therapeutics LLC
Condition(s)	Homozygous Familial Hypercholesterolemia
Phase	PHASE3
Listed sites	12
Site countries	United States, India, Israel, Norway, South Africa, Turkey (Türkiye)

Patient-friendly overview of this study: eichor.com/study/NCT04034485.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT04034485 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →